Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744907 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL11857583 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL4346958 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL28070085 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL11512940 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL11865856 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL9244508 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL4334523 | 1.00 | TSHR (0.64) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL7208906 | 0.98 | TSHR (0.61) | TSHRLMNAALDH1A1KMT2ARECQL | |
| SCHEMBL5098798 | 0.98 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712467-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-08-01 | — | — | US | disclosed |
| CN-112979693-B | Alkyl trimethyl tin compounds, and preparation method and application thereof | 天津师范大学 | 2023-03-28 | — | — | CN | disclosed |
| US-20220362375-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-17 | — | — | US | disclosed |
| US-11357848-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-06-14 | — | — | US | disclosed |
| CN-112979693-A | Alkyl trimethyl tin compounds, and preparation method and application thereof | 天津师范大学 | 2021-06-18 | — | — | CN | disclosed |
| US-20180125969-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-05-10 | — | — | US | disclosed |
| US-9884114-B2 | Methods of rational nicotine hapten design and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-02-06 | — | — | US | disclosed |
| EP-2027081-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20160375131-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2016-12-29 | — | — | US | disclosed |
| US-20150342961-A1 | USE OF PROSTAGLANDIN E1 (PGE1) AND MISOPROSTOL FOR TREATING CHRONIC MYELOGENOUS/MYELOID LEUKEMIA (CML) | Xue hai-hui (US) | 2015-12-03 | — | — | US | disclosed |
| WO-1994002478-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1994-02-03 | — | — | WO | disclosed |
| US-5266724-A | Magnetic recording media lubricant | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1993-11-30 | — | — | US | disclosed |
| US-5188747-A | Utilized in magnetic recording media for lubrication and rust prevention | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1993-02-23 | — | — | US | disclosed |
| EP-0473871-A2 | Fluorine-containing compounds | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1992-03-11 | — | — | EP | disclosed |
| EP-0178139-B1 | PROCESS FOR PRODUCING 2,3-DISUBSTITUTED -4-SUBSTITUTED CYCLOPENTANONES, ENANTIOMORPHS, OR MIXTURES THEREOF | TEIJIN LIMITED (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0178139-A2 | Process for producing 2,3-disubstituted -4-substituted cyclopentanones, enantiomorphs, or mixtures thereof | TEIJIN LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
| US-3996263-A | ANTIULCER | SANKYO COMPANY LIMITED (JA) | 1976-12-07 | — | — | US | disclosed |
| US-3987087-A | ANTI-ULCER, NASAL PATENCY, WOUND HEALING, LABOR INDUCEMENT | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3983152-A | OXYTOCICS | SANKYO COMPANY LIMITED (JA) | 1976-09-28 | — | — | US | disclosed |
| US-3953499-A | 8,12-Dialkyl-PGE, and PGF1.sub.α | THE UPJOHN COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362375-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | NAPRT, CHRNG, CHRNB2 | TSHR 1406/4885LMNA 4714/4885ALDH1A1 655/4885 |
| US-11712467-B2 | Methods of rational nicotine hapten design and uses thereof | NAPRT, CHRNG, CHRNB2 | TSHR 1406/4885LMNA 4714/4885ALDH1A1 655/4885 |
| US-20160375131-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | NAPRT, CHRNG, CHRNB2 | TSHR 1406/4885LMNA 4714/4885ALDH1A1 655/4885 |
| US-11357848-B2 | Methods of rational nicotine hapten design and uses thereof | NAPRT, CHRNG, CHRNB2 | TSHR 1406/4885LMNA 4714/4885ALDH1A1 655/4885 |
| US-20180125969-A1 | METHODS OF RATIONAL NICOTINE HAPTEN DESIGN AND USES THEREOF | NAPRT, CHRNG, CHRNB2 | TSHR 1406/4885LMNA 4714/4885ALDH1A1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.